ATE374838T1 - Nukleotidsequenzvariation im gen ns5a als marker - Google Patents

Nukleotidsequenzvariation im gen ns5a als marker

Info

Publication number
ATE374838T1
ATE374838T1 AT05008605T AT05008605T ATE374838T1 AT E374838 T1 ATE374838 T1 AT E374838T1 AT 05008605 T AT05008605 T AT 05008605T AT 05008605 T AT05008605 T AT 05008605T AT E374838 T1 ATE374838 T1 AT E374838T1
Authority
AT
Austria
Prior art keywords
marker
nucleotide sequence
sequence variation
ns5a gene
ns5a
Prior art date
Application number
AT05008605T
Other languages
English (en)
Inventor
Andrew Michael Ackrill
Karina Anna Orle
Morris Paterson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE374838T1 publication Critical patent/ATE374838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05008605T 2004-04-29 2005-04-20 Nukleotidsequenzvariation im gen ns5a als marker ATE374838T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56627404P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
ATE374838T1 true ATE374838T1 (de) 2007-10-15

Family

ID=34935435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05008605T ATE374838T1 (de) 2004-04-29 2005-04-20 Nukleotidsequenzvariation im gen ns5a als marker

Country Status (8)

Country Link
US (2) US7504217B2 (de)
EP (1) EP1591539B1 (de)
JP (1) JP4097662B2 (de)
CN (1) CN100422346C (de)
AT (1) ATE374838T1 (de)
CA (1) CA2503336A1 (de)
DE (1) DE602005002673T2 (de)
ES (1) ES2294589T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307589A (zh) * 2008-08-28 2012-01-04 沃泰克斯药物股份有限公司 Hcv的基因型分析
US8975247B2 (en) * 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
MX2012011804A (es) * 2010-04-13 2012-12-17 Hoffmann La Roche Polimorfismos de un solo nucleotido que predicen resultados de tratamiento de hcv.
US9175332B2 (en) * 2010-07-29 2015-11-03 Roche Molecular Systems, Inc. Generic PCR
US20120077738A1 (en) * 2010-09-24 2012-03-29 Wisconsin Alumni Research Foundation Compositions and methods for predicting hcv susceptibility to antiviral agents
KR101247769B1 (ko) 2011-02-18 2013-03-25 한림대학교 산학협력단 인터페론 알파 저항성 ｃ형 간염 바이러스
AU2013205064B2 (en) * 2012-06-04 2015-07-30 Gen-Probe Incorporated Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
CN107699636B (zh) * 2017-11-10 2019-03-15 黑龙江金域医学检验所有限公司 用于检测HCV 2a亚型NS5A耐药突变基因的扩增引物、应用及检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433159B1 (en) * 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
AUPN976596A0 (en) 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
AU726374B2 (en) * 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
US20030028011A1 (en) 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
EP1175224B1 (de) 1999-05-04 2005-02-23 Schering Corporation Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv therapie
KR100801123B1 (ko) * 2000-08-17 2008-02-05 트리펩 아베 리바비린 함유 백신 및 이것의 사용 방법
CN1093172C (zh) * 2001-03-19 2002-10-23 杨凌岱鹰生物工程股份有限公司 丙型肝炎全病毒及其体外细胞培养方法
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
KR100520529B1 (ko) * 2003-09-16 2005-10-11 현대자동차주식회사 차량용 6속 자동 변속기의 유압 제어시스템

Also Published As

Publication number Publication date
CN100422346C (zh) 2008-10-01
EP1591539A1 (de) 2005-11-02
US20090148831A1 (en) 2009-06-11
DE602005002673T2 (de) 2008-07-24
US7504217B2 (en) 2009-03-17
JP4097662B2 (ja) 2008-06-11
JP2005312454A (ja) 2005-11-10
US20050260567A1 (en) 2005-11-24
CN1693482A (zh) 2005-11-09
ES2294589T3 (es) 2008-04-01
DE602005002673D1 (de) 2007-11-15
EP1591539B1 (de) 2007-10-03
CA2503336A1 (en) 2005-10-29

Similar Documents

Publication Publication Date Title
DE602005009702D1 (de) Esr1 und gebärmutterhalskrebs
MXPA05005945A (es) Evento asr-368 de agrostis y composiciones y metodos para deteccion del mismo.
WO2001090419A3 (en) Methods for genetic analysis of dna to detect sequence variances
DE60322880D1 (de) Einfache katalytische dna-biosensoren für ionen auf grundlage von farbveränderungen
DE602005016892D1 (de) Nukleinsäurecharakterisierung
ATE402188T1 (de) Bindungsproteine als biosensoren
IL177495A0 (en) Methods of isolating and identifying cells using signaling probes
DK1842920T3 (da) Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
ATE374838T1 (de) Nukleotidsequenzvariation im gen ns5a als marker
DK2311869T3 (da) Anvendelse af pattedyrcytokinrelaterede reagenser
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
EP1639127A4 (de) Genetische typisierung auf dna-chip-basis
Laidlaw et al. Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
DE602004023766D1 (de) Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie
ATE441728T1 (de) Mit cmv-resistenz assoziierter molekularer marker und verwendung davon
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
DK1814907T3 (da) Sæt af dele til designet til implementering af en antitumoral eller antiviral behandling hos et pattedyr
MXPA05005120A (es) Secuencias de adn de la region genomica tcd de photorhabdus luminescens.
Lopez‐Rodriguez et al. Genetic Variants of Interferon‐Stimulated Genes and IL‐28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C
SE9900615L (sv) Metod och kit för tidig förutsägelse av cancer
DE602004027086D1 (de) Klassifizierung von kolonkrebs
WO2006012356A3 (en) Methods for determining risk of developing regular smoking behavior
ATE319739T1 (de) Menschliche wingless-änhliche gene
EP1907577A4 (de) Verfahren zum screening auf genspezifische hybridisierungspolymorphismen (gshp) und deren verwendung bei der genetischen kartierung und markerentwicklung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties